• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis.

作者信息

De Stefano Valerio, Rossi Elena, Za Tommaso, Ciminello Angela, Betti Silvia, Luzzi Claudia, Leone Giuseppe, Chiusolo Patrizia

机构信息

Institute of Hematology, Catholic University, Rome, Italy.

出版信息

Am J Hematol. 2011 Jun;86(6):526-8. doi: 10.1002/ajh.22024.

DOI:10.1002/ajh.22024
PMID:21594892
Abstract
摘要

相似文献

1
JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis.与内脏或脑静脉血栓形成相关的原发性血小板增多症中JAK2 V617F突变频率
Am J Hematol. 2011 Jun;86(6):526-8. doi: 10.1002/ajh.22024.
2
Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan.在伴有JAK2（V617F）突变的原发性血小板增多症的任何阶段都可能发生血栓形成：日本一项单中心研究
Leukemia. 2007 Jul;21(7):1570-1. doi: 10.1038/sj.leu.2404666. Epub 2007 Mar 29.
3
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.携带 JAK2 V617F 突变纯合子的原发性血小板增多症患者复发性血栓形成风险增加。
Ann Hematol. 2010 Feb;89(2):141-6. doi: 10.1007/s00277-009-0788-5. Epub 2009 Jul 7.
4
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.内脏或脑静脉血栓形成且无明显慢性骨髓增殖性疾病患者中JAK2 V617F突变的发生率。
J Thromb Haemost. 2007 Apr;5(4):708-14. doi: 10.1111/j.1538-7836.2007.02424.x. Epub 2007 Jan 29.
5
JAK2 mutations across a spectrum of venous thrombosis cases.JAK2 突变与一系列静脉血栓病例。
Am J Clin Pathol. 2010 Jul;134(1):82-5. doi: 10.1309/AJCP7VO4HAIZYATP.
6
JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia.JAK2 V617F、止血多态性及临床特征作为原发性血小板增多症患者动脉血栓形成事件的危险因素
Ann Hematol. 2008 Sep;87(9):763-5. doi: 10.1007/s00277-008-0474-z. Epub 2008 Mar 26.
7
JAK2 V617F: implications for thrombosis in myeloproliferative diseases.JAK2 V617F：对骨髓增殖性疾病中血栓形成的影响
Curr Opin Hematol. 2007 Sep;14(5):450-4. doi: 10.1097/MOH.0b013e3282861d1b.
8
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.原发性血小板增多症中的血小板周转率、凝血因子以及血小板和内皮细胞活化的可溶性标志物：与血栓形成及JAK2 V617F等位基因负荷的关系
Am J Hematol. 2009 Feb;84(2):102-8. doi: 10.1002/ajh.21338.
9
Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.雌激素孕激素治疗期间伴有内脏血栓形成的jak2 val617phe阳性原发性血小板增多症的证据。
Blood Coagul Fibrinolysis. 2008 Jul;19(5):453-7. doi: 10.1097/MBC.0b013e3283079e46.
10
Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.JAK2V617F突变对原发性血小板增多症中血栓形成和髓系转化的影响：141例患者的Cox回归多因素分析
Hematology. 2010 Aug;15(4):187-92. doi: 10.1179/102453309X12583347113933.

引用本文的文献

1
Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia.原发性血小板增多症患者脑静脉窦血栓形成的临床特征与管理
Neuropsychiatr Dis Treat. 2021 Apr 22;17:1195-1206. doi: 10.2147/NDT.S294712. eCollection 2021.
2
Complex intracranial vascular complications caused by essential thrombocythemia: a critical case report.由原发性血小板增多症引起的复杂颅内血管并发症：一例危急病例报告。
BMC Neurol. 2020 Nov 7;20(1):407. doi: 10.1186/s12883-020-01986-9.
3
Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis.
原发性血小板增多症：对血栓形成危险因素和预后的止血观点。
Mol Biol Rep. 2020 Jun;47(6):4767-4778. doi: 10.1007/s11033-020-05536-x. Epub 2020 May 30.
4
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.骨髓增殖性肿瘤相关静脉血栓栓塞症的抗血栓治疗。
Blood Cancer J. 2018 Jun 26;8(7):65. doi: 10.1038/s41408-018-0101-8.
5
Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.费城阴性经典骨髓增殖性肿瘤中的血栓形成：流行病学、风险评估和病理生理机制的叙述性综述。
J Thromb Thrombolysis. 2018 May;45(4):516-528. doi: 10.1007/s11239-018-1623-4.
6
The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.JAK2V617F突变对原发性血小板增多症患者不同类型血栓形成风险的影响：一项荟萃分析。
Int J Hematol. 2015 Aug;102(2):170-80. doi: 10.1007/s12185-015-1808-y. Epub 2015 May 22.
7
Budd-Chiari Syndrome in a Patient with JAK-2 V617F and Factor V G1691A Mutations.一名患有JAK-2 V617F和凝血因子V G1691A突变的患者的布加综合征
West Indian Med J. 2014 Sep;63(5):528-31. doi: 10.7727/wimj.2013.228. Epub 2014 Jun 10.
8
Initial management of noncirrhotic splanchnic vein thrombosis: when is anticoagulation enough?非肝硬化性内脏静脉血栓形成的初始治疗：抗凝治疗足够了吗？
Can J Gastroenterol Hepatol. 2014 Apr;28(4):207-11. doi: 10.1155/2014/353672.
9
Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis.脑静脉血栓形成患者的危险因素和复发性血栓事件。
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s337-42. doi: 10.2450/2013.0196-12. Epub 2013 Feb 6.
10
Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.Janus 激酶 2 V617F 等位基因负担与骨髓增殖性肿瘤临床血液学参数的相关性。
Ann Lab Med. 2012 Nov;32(6):385-91. doi: 10.3343/alm.2012.32.6.385. Epub 2012 Oct 17.